Emcure Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Emcure Pharmaceuticals has a total shareholder equity of ₹31.2B and total debt of ₹20.9B, which brings its debt-to-equity ratio to 66.9%. Its total assets and total liabilities are ₹78.1B and ₹46.8B respectively. Emcure Pharmaceuticals's EBIT is ₹9.7B making its interest coverage ratio 4.1. It has cash and short-term investments of ₹5.3B.
Key information
66.9%
Debt to equity ratio
₹20.87b
Debt
Interest coverage ratio | 4.1x |
Cash | ₹5.32b |
Equity | ₹31.22b |
Total liabilities | ₹46.84b |
Total assets | ₹78.06b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: EMCURE's short term assets (₹42.6B) exceed its short term liabilities (₹32.1B).
Long Term Liabilities: EMCURE's short term assets (₹42.6B) exceed its long term liabilities (₹14.7B).
Debt to Equity History and Analysis
Debt Level: EMCURE's net debt to equity ratio (49.8%) is considered high.
Reducing Debt: EMCURE's debt to equity ratio has reduced from 112.4% to 66.9% over the past 5 years.
Debt Coverage: EMCURE's debt is well covered by operating cash flow (52.6%).
Interest Coverage: EMCURE's interest payments on its debt are well covered by EBIT (4.1x coverage).